<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972816</url>
  </required_header>
  <id_info>
    <org_study_id>V112_02</org_study_id>
    <nct_id>NCT00972816</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to &lt; 9 Years)</brief_title>
  <official_title>A Pivotal Randomized, Single-Blind, Dose-Finding Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Pediatric Subjects 3 to &lt; 9 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immunogenicity of different combinations of A/H1N1
      S-OIV (swine flu) vaccine in healthy young children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Responses According to the Hemagglutinin Inhibition (HI) Assay After the First and Second Vaccinations</measure>
    <time_frame>Day 22, Day 29, Day 43, Day 202 and Day 387</time_frame>
    <description>HI antibody assay (used to assess immune responses in subjects following vaccination) according to the Center for Biologics Evaluation and Research (CBER) guidance for &lt;65 years of age: The lower bound of the two-sided 95% Confidence Interval (CI) for the percentages of subjects achieving seroconversion for HI antibody should be ≥ 40% and the lower bound of the two-sided 95% CI for the percentages of subjects achieving an HI antibody titer ≥ 1:40 should be ≥ 70%. Both criteria (seroconversion and HI antibody titer ≥ 40) had to be fulfilled to establish immunogenicity.
PPS Day 1-29 analysis set: N= 143, 149, 149, 146, 147, 147, 144, and 144 for Groups A, B, C, D, E, F,G,and H respectively.
PPS Day 1-202 analysis set: N= 82, 85, 84, 84, 86, 87, 82, and 79 for Groups A, B, C, D, E, F, G, and H respectively.
PPS Day 1-387 analysis set: N= 55, 63, 61, 58, 61, 65, 59, and 63 for Groups A, B, C, D, E, F, G, and H respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) After Each Vaccination by Vaccine Group</measure>
    <time_frame>Day 22, Day 29, Day 43, Day 202 and Day 387</time_frame>
    <description>Immunogenicity was measured in terms of GMTs After each vaccination by vaccine Group.
PPS Day1-29 analysis set: N=143, 149, 149, 146, 147, 147, 144, and 144 for Groups A, B, C, D, E, F, G, and H respectively.
PPS Day 1-202 analysis set. N= 82, 85, 84, 84, 86, 87, 82, and 79 for Groups A, B, C, D, E, F, G, and H respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Responses With and Without Seasonal Influenza Vaccination for Year 2009 to 2010.</measure>
    <time_frame>Day 22, Day 29, Day 43</time_frame>
    <description>HI antibody assay (used to assess immune responses in subjects following vaccination) according to the Committee for Medicinal Products for Human Use (CHMP) guidance: in adults ages 18 to 60 years are:The percentage of subjects with seroconversion or significant increase in HI antibody is &gt; 40%.The percentage of subjects achieving an HI titer ≥ 40 is &gt; 70% and The GMR is &gt; 2.5. All 3 criteria (seroconversion/significant increase, HI antibody titer ≥ 40, and GMR) had to be fulfilled to establish immunogenicity.Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.Subgroups without recent seasonal flu vaccine:PPS Day1, Day 1-22 and Day1-43 analysis set. N= 141, 147, 150, 148, 146, 146, 150, and 146 for Groups A, B, C, D, E, F, G, and H respectively. PPS Day 1-29 analysis set. N= 132, 140, 143, 139, 138, 136, 139, and 138 for Groups A, B, C, D, E, F, G,and H respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</measure>
    <time_frame>Day 1, Day 22, Day 29, Day 43</time_frame>
    <description>Immunogenicity was measured in terms of GMTs of Subgroups with receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines
Subgroups without recent seasonal flu vaccine:
PPS Day 1, Day 1-22 and Day 1-43 analysis set. N= 141, 147, 150, 148, 146, 146, 150, and 146 for Groups A, B, C, D, E, F, G, and H respectively.
PPS Day 1-29 analysis set. N= 132, 140, 143, 139, 138, 136, 139, and 138 for Groups A, B, C, D, E, F,G, and H respectively.
Subgroups with recent seasonal flu vaccine:PPS Day 1-22 and Day 1-43 analysis set. N= 11, 9, 6, 8, 9, 11, 6, and 7 for Groups A, B, C, D, E, F, G,and H respectively.
PPS Day 1-29 analysis set. N= 11, 9, 6, 7, 9, 11, 5, and 6 for Groups A, B, C, D, E, F, G, and H respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Response Based on Baseline Seropositivity</measure>
    <time_frame>Day 22, Day 29 and Day 43</time_frame>
    <description>Subgroup analysis based on Subjects with seropositivity (pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10) at baseline.
Subgroups with baseline HI titer &lt; 1:10: PPS Day 1-29 analysis set. N= 104, 116, 111, 107, 109, 113,120, and 103 for Groups A, B, C, D, E, F, G, and H respectively.
Subgroups with baseline HI titer ≥ 1:10: PPS Day 1-29 analysis set. N= 39, 33, 38, 39, 38, 34, 24, and 41 for Groups A, B, C, D, E, F, G, and H respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) Based on Baseline Seropositivity</measure>
    <time_frame>Day 1, Day 22, Day 29, Day 43</time_frame>
    <description>Subgroup analysis based on Subjects with seropositivity (pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10) at baseline.
Immunogenicity responses in subjects who are seropositive (A/H1N1 2009 HI titer ≥ 1:10) at Baseline [Day 1 (pre-vaccination)] as compared to those who are seronegative (HI titer &lt; 1:10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Symptoms After the First Vaccination</measure>
    <time_frame>7 days after first vaccination</time_frame>
    <description>Solicited local and systemic reactions were assessed after the first vaccination by vaccine group. Source Vocabulary Name: MedDRA (13.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Symptoms After the Second Vaccination</measure>
    <time_frame>7 days after second vaccination</time_frame>
    <description>Solicited local and systemic reactions were assessed after the second vaccination by vaccine group.Source Vocabulary Name: MedDRA (13.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Safety monitoring periods were the Primary Period: Day 1 (1st vaccination) through ≤21 days post second vaccination, and the Follow-up Period: &gt;21 Days post second vaccination to 12 months after second vaccination</time_frame>
    <description>Safety was measured in terms of the Number of Participants Reporting Unsolicited AEs. Source Vocabulary Name: MedDRA (13.1)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">1357</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>3.75_(50)MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.75 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5_(0) MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5_(50) MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5_(100) MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15_(0) MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15_(50)MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15_(100) MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30_(0) MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eH1N1</intervention_name>
    <description>MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).</description>
    <arm_group_label>3.75_(50)MF59</arm_group_label>
    <arm_group_label>7.5_(0) MF59</arm_group_label>
    <arm_group_label>7.5_(50) MF59</arm_group_label>
    <arm_group_label>7.5_(100) MF59</arm_group_label>
    <arm_group_label>15_(0) MF59</arm_group_label>
    <arm_group_label>15_(50)MF59</arm_group_label>
    <arm_group_label>15_(100) MF59</arm_group_label>
    <arm_group_label>30_(0) MF59</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 3 to &lt; 9 years of age in good health as determined by medical history,
             physical assessment and clinical judgement of the investigator and without influenza
             within the past 6 months.

        Exclusion Criteria:

          -  History of serious disease.

          -  History of serious reaction following administration of vaccine or hypersensitivity to
             vaccine components.

          -  Known or suspected impairment/alteration of immune function.

          -  Receipt or planned receipt of seasonal trivalent influenza vaccine within 1 week
             before or after each study vaccination.

        For additional entry criteria, please refer to protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premier Health Research Center, LLC</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241-4982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madera Family Medical Group</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clincal Trials, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials of San Gabriel</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st International Research Centers</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics and Adolescent Medicine</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics and Adolescent Medicine</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Illinois Research Associates</name>
      <address>
        <city>Dekalb</city>
        <state>Illinois</state>
        <zip>60115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Clinical Research, Inc.</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates LLC</name>
      <address>
        <city>Arkansas City</city>
        <state>Kansas</state>
        <zip>67005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Clinical Research, Inc (Brownsboro for drug shipment)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Pediatrics and Adolescent Ctr.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Senders and Associates, Pediatrics</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prestige Clinical Research</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Portland Clinic LLP</name>
      <address>
        <city>Beaverton</city>
        <state>Oregon</state>
        <zip>97006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Health Care -West</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC/Community Medicine (pediatrics)</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Physicians Research, Inc.</name>
      <address>
        <city>Jefferson Hills</city>
        <state>Pennsylvania</state>
        <zip>15025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Alliance - Greentree Division (pediatrics)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Clinical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Service</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Healthcare of NW Houston</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.Lewis Research, Inc./Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc./Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PI-Coor Clinical Research</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockwood Research Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias</name>
      <address>
        <city>Tlalpan</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <results_first_submitted>December 6, 2010</results_first_submitted>
  <results_first_submitted_qc>January 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2011</results_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Swine Flu</keyword>
  <keyword>Flu</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Children</keyword>
  <keyword>Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>MF59 oil emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>36 centers in the U.S., of which 34 centers enrolled subjects.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>3.75_(50) MF59</title>
          <description>3.75 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22</description>
        </group>
        <group group_id="P2">
          <title>7.5_(0) MF59</title>
          <description>7.5 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22</description>
        </group>
        <group group_id="P3">
          <title>7.5_(50)MF59</title>
          <description>7.5 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22</description>
        </group>
        <group group_id="P4">
          <title>7.5_(100)MF59</title>
          <description>7.5 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22</description>
        </group>
        <group group_id="P5">
          <title>15_(0) MF59</title>
          <description>15 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22</description>
        </group>
        <group group_id="P6">
          <title>15_(50) MF59</title>
          <description>15 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22</description>
        </group>
        <group group_id="P7">
          <title>15_(100) MF59</title>
          <description>15 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22</description>
        </group>
        <group group_id="P8">
          <title>30_(0) MF59</title>
          <description>30 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="169"/>
                <participants group_id="P4" count="169"/>
                <participants group_id="P5" count="169"/>
                <participants group_id="P6" count="169"/>
                <participants group_id="P7" count="169"/>
                <participants group_id="P8" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="161"/>
                <participants group_id="P5" count="157"/>
                <participants group_id="P6" count="158"/>
                <participants group_id="P7" count="159"/>
                <participants group_id="P8" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrolment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3.75_(50)MF59</title>
          <description>50% of MF59 with 3.75 µg A/H1N1 antigen</description>
        </group>
        <group group_id="B2">
          <title>7.5 Without MF59</title>
          <description>1 dose of 7.5 µg A/H1N1</description>
        </group>
        <group group_id="B3">
          <title>7.5_(50)MF59</title>
          <description>50% of MF59 with 7.5 µg A/H1N1 antigen</description>
        </group>
        <group group_id="B4">
          <title>7.5_(100)MF59</title>
          <description>100% of MF59 with 7.5 µg A/H1N1 antigen</description>
        </group>
        <group group_id="B5">
          <title>15 Without MF59</title>
          <description>1 dose of 15 µg A/H1N1</description>
        </group>
        <group group_id="B6">
          <title>15_(50)MF59</title>
          <description>50% of MF59 with 15 µg A/H1N1 antigen</description>
        </group>
        <group group_id="B7">
          <title>15_(100)MF59</title>
          <description>100% of MF59 with 15 µg A/H1N1 antigen</description>
        </group>
        <group group_id="B8">
          <title>30 Without MF59</title>
          <description>1 dose of 30 µg A/H1N1</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="173"/>
            <count group_id="B2" value="169"/>
            <count group_id="B3" value="169"/>
            <count group_id="B4" value="169"/>
            <count group_id="B5" value="169"/>
            <count group_id="B6" value="169"/>
            <count group_id="B7" value="169"/>
            <count group_id="B8" value="170"/>
            <count group_id="B9" value="1357"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="1.7"/>
                    <measurement group_id="B2" value="5.2" spread="1.7"/>
                    <measurement group_id="B3" value="5.5" spread="1.8"/>
                    <measurement group_id="B4" value="5.9" spread="1.7"/>
                    <measurement group_id="B5" value="5.6" spread="1.7"/>
                    <measurement group_id="B6" value="5.5" spread="1.7"/>
                    <measurement group_id="B7" value="5.5" spread="1.7"/>
                    <measurement group_id="B8" value="5.5" spread="1.7"/>
                    <measurement group_id="B9" value="5.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="79"/>
                    <measurement group_id="B6" value="80"/>
                    <measurement group_id="B7" value="75"/>
                    <measurement group_id="B8" value="83"/>
                    <measurement group_id="B9" value="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="90"/>
                    <measurement group_id="B6" value="89"/>
                    <measurement group_id="B7" value="94"/>
                    <measurement group_id="B8" value="87"/>
                    <measurement group_id="B9" value="705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Responses According to the Hemagglutinin Inhibition (HI) Assay After the First and Second Vaccinations</title>
        <description>HI antibody assay (used to assess immune responses in subjects following vaccination) according to the Center for Biologics Evaluation and Research (CBER) guidance for &lt;65 years of age: The lower bound of the two-sided 95% Confidence Interval (CI) for the percentages of subjects achieving seroconversion for HI antibody should be ≥ 40% and the lower bound of the two-sided 95% CI for the percentages of subjects achieving an HI antibody titer ≥ 1:40 should be ≥ 70%. Both criteria (seroconversion and HI antibody titer ≥ 40) had to be fulfilled to establish immunogenicity.
PPS Day 1–29 analysis set: N= 143, 149, 149, 146, 147, 147, 144, and 144 for Groups A, B, C, D, E, F,G,and H respectively.
PPS Day 1–202 analysis set: N= 82, 85, 84, 84, 86, 87, 82, and 79 for Groups A, B, C, D, E, F, G, and H respectively.
PPS Day 1–387 analysis set: N= 55, 63, 61, 58, 61, 65, 59, and 63 for Groups A, B, C, D, E, F, G, and H respectively.</description>
        <time_frame>Day 22, Day 29, Day 43, Day 202 and Day 387</time_frame>
        <population>The analysis was performed on per protocol set (PPS) population</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>50% of MF59 with 3.75 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O2">
            <title>7.5 Without MF59</title>
            <description>1 dose of 7.5 µg A/H1N1</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>50% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O4">
            <title>7.5_(100)MF59</title>
            <description>100% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O5">
            <title>15 Without MF59</title>
            <description>1 dose of 15 µg A/H1N1</description>
          </group>
          <group group_id="O6">
            <title>15_(50)MF59</title>
            <description>50% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O7">
            <title>15_(100)MF59</title>
            <description>100% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O8">
            <title>30 Without MF59</title>
            <description>1 dose of 30 µg A/H1N1</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Responses According to the Hemagglutinin Inhibition (HI) Assay After the First and Second Vaccinations</title>
          <description>HI antibody assay (used to assess immune responses in subjects following vaccination) according to the Center for Biologics Evaluation and Research (CBER) guidance for &lt;65 years of age: The lower bound of the two-sided 95% Confidence Interval (CI) for the percentages of subjects achieving seroconversion for HI antibody should be ≥ 40% and the lower bound of the two-sided 95% CI for the percentages of subjects achieving an HI antibody titer ≥ 1:40 should be ≥ 70%. Both criteria (seroconversion and HI antibody titer ≥ 40) had to be fulfilled to establish immunogenicity.
PPS Day 1–29 analysis set: N= 143, 149, 149, 146, 147, 147, 144, and 144 for Groups A, B, C, D, E, F,G,and H respectively.
PPS Day 1–202 analysis set: N= 82, 85, 84, 84, 86, 87, 82, and 79 for Groups A, B, C, D, E, F, G, and H respectively.
PPS Day 1–387 analysis set: N= 55, 63, 61, 58, 61, 65, 59, and 63 for Groups A, B, C, D, E, F, G, and H respectively.</description>
          <population>The analysis was performed on per protocol set (PPS) population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="155"/>
                <count group_id="O6" value="157"/>
                <count group_id="O7" value="156"/>
                <count group_id="O8" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI titer ≥1:40 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6" upper_limit="17"/>
                    <measurement group_id="O2" value="9" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="O3" value="13" lower_limit="8" upper_limit="19"/>
                    <measurement group_id="O4" value="11" lower_limit="6" upper_limit="170"/>
                    <measurement group_id="O5" value="15" lower_limit="10" upper_limit="22"/>
                    <measurement group_id="O6" value="9" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="O7" value="8" lower_limit="4" upper_limit="13"/>
                    <measurement group_id="O8" value="12" lower_limit="8" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="77" upper_limit="89"/>
                    <measurement group_id="O2" value="48" lower_limit="40" upper_limit="56"/>
                    <measurement group_id="O3" value="81" lower_limit="74" upper_limit="87"/>
                    <measurement group_id="O4" value="91" lower_limit="85" upper_limit="95"/>
                    <measurement group_id="O5" value="61" lower_limit="52" upper_limit="68"/>
                    <measurement group_id="O6" value="82" lower_limit="75" upper_limit="88"/>
                    <measurement group_id="O7" value="94" lower_limit="89" upper_limit="97"/>
                    <measurement group_id="O8" value="65" lower_limit="57" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="74" upper_limit="87"/>
                    <measurement group_id="O2" value="46" lower_limit="38" upper_limit="54"/>
                    <measurement group_id="O3" value="78" lower_limit="70" upper_limit="84"/>
                    <measurement group_id="O4" value="88" lower_limit="82" upper_limit="93"/>
                    <measurement group_id="O5" value="58" lower_limit="50" upper_limit="66"/>
                    <measurement group_id="O6" value="82" lower_limit="75" upper_limit="87"/>
                    <measurement group_id="O7" value="92" lower_limit="86" upper_limit="95"/>
                    <measurement group_id="O8" value="60" lower_limit="52" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="79" lower_limit="71" upper_limit="85"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O4" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O5" value="88" lower_limit="82" upper_limit="93"/>
                    <measurement group_id="O6" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O8" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="78" lower_limit="70" upper_limit="84"/>
                    <measurement group_id="O3" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O4" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O5" value="87" lower_limit="81" upper_limit="92"/>
                    <measurement group_id="O6" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O8" value="94" lower_limit="88" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="79" lower_limit="72" upper_limit="85"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O4" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O5" value="87" lower_limit="81" upper_limit="92"/>
                    <measurement group_id="O6" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O8" value="92" lower_limit="86" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="78" lower_limit="70" upper_limit="84"/>
                    <measurement group_id="O3" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O4" value="97" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O5" value="85" lower_limit="78" upper_limit="90"/>
                    <measurement group_id="O6" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O7" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O8" value="88" lower_limit="82" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 day 202 (N=82,85,84,84,86,87,82,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="88" upper_limit="99"/>
                    <measurement group_id="O2" value="65" lower_limit="54" upper_limit="75"/>
                    <measurement group_id="O3" value="93" lower_limit="85" upper_limit="97"/>
                    <measurement group_id="O4" value="95" lower_limit="88" upper_limit="99"/>
                    <measurement group_id="O5" value="74" lower_limit="64" upper_limit="83"/>
                    <measurement group_id="O6" value="95" lower_limit="89" upper_limit="99"/>
                    <measurement group_id="O7" value="95" lower_limit="88" upper_limit="99"/>
                    <measurement group_id="O8" value="81" lower_limit="71" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion day 202 (N=82,85,84,84,86,87,82,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="73" upper_limit="90"/>
                    <measurement group_id="O2" value="55" lower_limit="44" upper_limit="66"/>
                    <measurement group_id="O3" value="83" lower_limit="74" upper_limit="91"/>
                    <measurement group_id="O4" value="83" lower_limit="74" upper_limit="91"/>
                    <measurement group_id="O5" value="63" lower_limit="52" upper_limit="73"/>
                    <measurement group_id="O6" value="90" lower_limit="81" upper_limit="95"/>
                    <measurement group_id="O7" value="90" lower_limit="82" upper_limit="96"/>
                    <measurement group_id="O8" value="66" lower_limit="54" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 day 387 (N=55,63,61,58,61,65,59,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="67" upper_limit="90"/>
                    <measurement group_id="O2" value="56" lower_limit="42" upper_limit="68"/>
                    <measurement group_id="O3" value="75" lower_limit="63" upper_limit="86"/>
                    <measurement group_id="O4" value="88" lower_limit="77" upper_limit="95"/>
                    <measurement group_id="O5" value="49" lower_limit="36" upper_limit="62"/>
                    <measurement group_id="O6" value="78" lower_limit="67" upper_limit="88"/>
                    <measurement group_id="O7" value="81" lower_limit="69" upper_limit="90"/>
                    <measurement group_id="O8" value="65" lower_limit="52" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion day 387 (N=55,63,61,58,61,65,59,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="51" upper_limit="78"/>
                    <measurement group_id="O2" value="49" lower_limit="36" upper_limit="62"/>
                    <measurement group_id="O3" value="69" lower_limit="56" upper_limit="80"/>
                    <measurement group_id="O4" value="78" lower_limit="65" upper_limit="87"/>
                    <measurement group_id="O5" value="44" lower_limit="32" upper_limit="58"/>
                    <measurement group_id="O6" value="75" lower_limit="63" upper_limit="85"/>
                    <measurement group_id="O7" value="71" lower_limit="58" upper_limit="82"/>
                    <measurement group_id="O8" value="51" lower_limit="38" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) After Each Vaccination by Vaccine Group</title>
        <description>Immunogenicity was measured in terms of GMTs After each vaccination by vaccine Group.
PPS Day1–29 analysis set: N=143, 149, 149, 146, 147, 147, 144, and 144 for Groups A, B, C, D, E, F, G, and H respectively.
PPS Day 1–202 analysis set. N= 82, 85, 84, 84, 86, 87, 82, and 79 for Groups A, B, C, D, E, F, G, and H respectively.</description>
        <time_frame>Day 22, Day 29, Day 43, Day 202 and Day 387</time_frame>
        <population>The analysis was performed on per protocol set (PPS) population</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>50% of MF59 with 3.75 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O2">
            <title>7.5 Without MF59</title>
            <description>1 dose of 7.5 µg A/H1N1</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>50% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O4">
            <title>7.5_(100)MF59</title>
            <description>100% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O5">
            <title>15 Without MF59</title>
            <description>1 dose of 15 µg A/H1N1</description>
          </group>
          <group group_id="O6">
            <title>15_(50)MF59</title>
            <description>50% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O7">
            <title>15_(100)MF59</title>
            <description>100% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O8">
            <title>30 Without MF59</title>
            <description>1 dose of 30 µg A/H1N1</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) After Each Vaccination by Vaccine Group</title>
          <description>Immunogenicity was measured in terms of GMTs After each vaccination by vaccine Group.
PPS Day1–29 analysis set: N=143, 149, 149, 146, 147, 147, 144, and 144 for Groups A, B, C, D, E, F, G, and H respectively.
PPS Day 1–202 analysis set. N= 82, 85, 84, 84, 86, 87, 82, and 79 for Groups A, B, C, D, E, F, G, and H respectively.</description>
          <population>The analysis was performed on per protocol set (PPS) population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="155"/>
                <count group_id="O6" value="157"/>
                <count group_id="O7" value="156"/>
                <count group_id="O8" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="O2" value="7.3" lower_limit="6" upper_limit="8.8"/>
                    <measurement group_id="O3" value="8.7" lower_limit="7.2" upper_limit="11"/>
                    <measurement group_id="O4" value="8.7" lower_limit="6.7" upper_limit="9.9"/>
                    <measurement group_id="O5" value="9.1" lower_limit="7.5" upper_limit="11"/>
                    <measurement group_id="O6" value="7.5" lower_limit="6.2" upper_limit="9.1"/>
                    <measurement group_id="O7" value="7" lower_limit="5.8" upper_limit="8.4"/>
                    <measurement group_id="O8" value="9.1" lower_limit="7.5" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMTs day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" lower_limit="78" upper_limit="148"/>
                    <measurement group_id="O2" value="27" lower_limit="20" upper_limit="37"/>
                    <measurement group_id="O3" value="88" lower_limit="64" upper_limit="121"/>
                    <measurement group_id="O4" value="163" lower_limit="118" upper_limit="223"/>
                    <measurement group_id="O5" value="49" lower_limit="36" upper_limit="68"/>
                    <measurement group_id="O6" value="106" lower_limit="77" upper_limit="145"/>
                    <measurement group_id="O7" value="160" lower_limit="116" upper_limit="220"/>
                    <measurement group_id="O8" value="62" lower_limit="45" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="747" lower_limit="588" upper_limit="950"/>
                    <measurement group_id="O2" value="138" lower_limit="109" upper_limit="174"/>
                    <measurement group_id="O3" value="685" lower_limit="542" upper_limit="866"/>
                    <measurement group_id="O4" value="984" lower_limit="775" upper_limit="1249"/>
                    <measurement group_id="O5" value="214" lower_limit="169" upper_limit="271"/>
                    <measurement group_id="O6" value="761" lower_limit="600" upper_limit="966"/>
                    <measurement group_id="O7" value="1070" lower_limit="841" upper_limit="1360"/>
                    <measurement group_id="O8" value="297" lower_limit="235" upper_limit="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMTs day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="560" lower_limit="450" upper_limit="699"/>
                    <measurement group_id="O2" value="113" lower_limit="91" upper_limit="140"/>
                    <measurement group_id="O3" value="480" lower_limit="386" upper_limit="597"/>
                    <measurement group_id="O4" value="637" lower_limit="511" upper_limit="793"/>
                    <measurement group_id="O5" value="174" lower_limit="140" upper_limit="217"/>
                    <measurement group_id="O6" value="524" lower_limit="420" upper_limit="652"/>
                    <measurement group_id="O7" value="778" lower_limit="625" upper_limit="969"/>
                    <measurement group_id="O8" value="223" lower_limit="179" upper_limit="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMTs day 202 (N=143,149,149,146,147,147,144,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="88" upper_limit="157"/>
                    <measurement group_id="O2" value="45" lower_limit="34" upper_limit="59"/>
                    <measurement group_id="O3" value="107" lower_limit="80" upper_limit="144"/>
                    <measurement group_id="O4" value="132" lower_limit="99" upper_limit="177"/>
                    <measurement group_id="O5" value="55" lower_limit="41" upper_limit="74"/>
                    <measurement group_id="O6" value="134" lower_limit="100" upper_limit="179"/>
                    <measurement group_id="O7" value="131" lower_limit="97" upper_limit="176"/>
                    <measurement group_id="O8" value="81" lower_limit="60" upper_limit="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMTs day 387 (N=55,63,61,58,61,65,59,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="37" upper_limit="78"/>
                    <measurement group_id="O2" value="28" lower_limit="20" upper_limit="40"/>
                    <measurement group_id="O3" value="57" lower_limit="40" upper_limit="82"/>
                    <measurement group_id="O4" value="70" lower_limit="49" upper_limit="102"/>
                    <measurement group_id="O5" value="30" lower_limit="21" upper_limit="42"/>
                    <measurement group_id="O6" value="59" lower_limit="41" upper_limit="83"/>
                    <measurement group_id="O7" value="63" lower_limit="44" upper_limit="90"/>
                    <measurement group_id="O8" value="45" lower_limit="31" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>3.998</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.659</ci_lower_limit>
            <ci_upper_limit>6.009</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>1.222</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.813</ci_lower_limit>
            <ci_upper_limit>1.838</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.661</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.440</ci_lower_limit>
            <ci_upper_limit>0.994</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>2.178</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.449</ci_lower_limit>
            <ci_upper_limit>3.276</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>1.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.676</ci_lower_limit>
            <ci_upper_limit>1.528</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.673</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.448</ci_lower_limit>
            <ci_upper_limit>1.012</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>1.742</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.156</ci_lower_limit>
            <ci_upper_limit>2.626</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.306</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.204</ci_lower_limit>
            <ci_upper_limit>0.458</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.165</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.110</ci_lower_limit>
            <ci_upper_limit>0.248</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.545</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.363</ci_lower_limit>
            <ci_upper_limit>0.818</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.254</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.170</ci_lower_limit>
            <ci_upper_limit>0.381</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.168</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.112</ci_lower_limit>
            <ci_upper_limit>0.252</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.436</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.290</ci_lower_limit>
            <ci_upper_limit>0.655</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.541</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.361</ci_lower_limit>
            <ci_upper_limit>0.811</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>1.783</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.188</ci_lower_limit>
            <ci_upper_limit>2.676</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.832</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.555</ci_lower_limit>
            <ci_upper_limit>1.246</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.551</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.367</ci_lower_limit>
            <ci_upper_limit>0.826</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>1.426</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.950</ci_lower_limit>
            <ci_upper_limit>2.140</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>3.295</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.196</ci_lower_limit>
            <ci_upper_limit>4.944</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>1.538</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.026</ci_lower_limit>
            <ci_upper_limit>2.303</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>1.018</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.679</ci_lower_limit>
            <ci_upper_limit>1.526</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>2.635</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.754</ci_lower_limit>
            <ci_upper_limit>3.959</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.467</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.311</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.309</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.206</ci_lower_limit>
            <ci_upper_limit>0.463</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.532</ci_lower_limit>
            <ci_upper_limit>1.203</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>0.662</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.442</ci_lower_limit>
            <ci_upper_limit>0.992</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>1.714</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.142</ci_lower_limit>
            <ci_upper_limit>2.572</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 22</param_type>
            <param_value>2.589</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.723</ci_lower_limit>
            <ci_upper_limit>3.889</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>4.975</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.757</ci_lower_limit>
            <ci_upper_limit>6.589</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>1.168</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.881</ci_lower_limit>
            <ci_upper_limit>1.547</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.880</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.665</ci_lower_limit>
            <ci_upper_limit>1.166</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>3.219</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.430</ci_lower_limit>
            <ci_upper_limit>4.264</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>1.070</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.808</ci_lower_limit>
            <ci_upper_limit>1.417</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.720</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.544</ci_lower_limit>
            <ci_upper_limit>0.954</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>2.509</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.891</ci_lower_limit>
            <ci_upper_limit>3.330</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.235</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.178</ci_lower_limit>
            <ci_upper_limit>0.310</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.177</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.134</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.647</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.489</ci_lower_limit>
            <ci_upper_limit>0.856</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.215</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.163</ci_lower_limit>
            <ci_upper_limit>0.284</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.145</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.109</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.504</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.381</ci_lower_limit>
            <ci_upper_limit>0.668</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.754</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.570</ci_lower_limit>
            <ci_upper_limit>0.997</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>2.756</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.083</ci_lower_limit>
            <ci_upper_limit>3.647</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.916</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.694</ci_lower_limit>
            <ci_upper_limit>1.211</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.616</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.466</ci_lower_limit>
            <ci_upper_limit>1.815</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>2.149</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.624</ci_lower_limit>
            <ci_upper_limit>2.843</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>3.656</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.764</ci_lower_limit>
            <ci_upper_limit>4.836</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>1.216</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.920</ci_lower_limit>
            <ci_upper_limit>1.606</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.818</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.619</ci_lower_limit>
            <ci_upper_limit>1.081</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>2.850</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.152</ci_lower_limit>
            <ci_upper_limit>3.773</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.332</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.251</ci_lower_limit>
            <ci_upper_limit>0.440</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.224</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.169</ci_lower_limit>
            <ci_upper_limit>0.296</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.780</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.588</ci_lower_limit>
            <ci_upper_limit>1.003</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>0.673</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.509</ci_lower_limit>
            <ci_upper_limit>0.889</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>2.345</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.772</ci_lower_limit>
            <ci_upper_limit>3.102</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 43</param_type>
            <param_value>3.485</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.633</ci_lower_limit>
            <ci_upper_limit>4.614</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>2.624</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.817</ci_lower_limit>
            <ci_upper_limit>3.789</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>1.096</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.760</ci_lower_limit>
            <ci_upper_limit>1.580</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.888</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.615</ci_lower_limit>
            <ci_upper_limit>1.282</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>2.120</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.473</ci_lower_limit>
            <ci_upper_limit>3.052</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.876</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.610</ci_lower_limit>
            <ci_upper_limit>1.260</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.898</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.622</ci_lower_limit>
            <ci_upper_limit>1.298</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>1.451</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.000</ci_lower_limit>
            <ci_upper_limit>2.105</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.418</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.289</ci_lower_limit>
            <ci_upper_limit>0.603</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.338</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.235</ci_lower_limit>
            <ci_upper_limit>0.487</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.808</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.561</ci_lower_limit>
            <ci_upper_limit>1.165</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.334</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.233</ci_lower_limit>
            <ci_upper_limit>0.479</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.342</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.237</ci_lower_limit>
            <ci_upper_limit>0.494</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.553</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.382</ci_lower_limit>
            <ci_upper_limit>0.801</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.811</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.562</ci_lower_limit>
            <ci_upper_limit>1.169</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>1.935</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.347</ci_lower_limit>
            <ci_upper_limit>2.780</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.800</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.558</ci_lower_limit>
            <ci_upper_limit>1.147</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.820</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.568</ci_lower_limit>
            <ci_upper_limit>1.184</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>1.324</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.915</ci_lower_limit>
            <ci_upper_limit>1.917</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>2.388</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.658</ci_lower_limit>
            <ci_upper_limit>3.438</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.987</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.688</ci_lower_limit>
            <ci_upper_limit>1.416</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>1.012</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.701</ci_lower_limit>
            <ci_upper_limit>1.460</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>1.634</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.128</ci_lower_limit>
            <ci_upper_limit>2.366</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.413</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.288</ci_lower_limit>
            <ci_upper_limit>0.592</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.424</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.294</ci_lower_limit>
            <ci_upper_limit>0.610</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>0.684</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.473</ci_lower_limit>
            <ci_upper_limit>0.990</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>1.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.714</ci_lower_limit>
            <ci_upper_limit>1.473</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>1.656</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.150</ci_lower_limit>
            <ci_upper_limit>2.385</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 202</param_type>
            <param_value>1.615</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.115</ci_lower_limit>
            <ci_upper_limit>2.339</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>1.906</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.177</ci_lower_limit>
            <ci_upper_limit>3.087</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.945</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.583</ci_lower_limit>
            <ci_upper_limit>1.533</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.763</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.468</ci_lower_limit>
            <ci_upper_limit>1.245</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>1.818</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.119</ci_lower_limit>
            <ci_upper_limit>2.956</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.917</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.568</ci_lower_limit>
            <ci_upper_limit>1.481</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.855</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.524</ci_lower_limit>
            <ci_upper_limit>1.396</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>1.203</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.745</ci_lower_limit>
            <ci_upper_limit>1.943</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.496</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.310</ci_lower_limit>
            <ci_upper_limit>0.794</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.400</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.250</ci_lower_limit>
            <ci_upper_limit>0.641</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.954</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.596</ci_lower_limit>
            <ci_upper_limit>1.528</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.481</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.306</ci_lower_limit>
            <ci_upper_limit>0.758</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.449</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.279</ci_lower_limit>
            <ci_upper_limit>0.722</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.631</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.398</ci_lower_limit>
            <ci_upper_limit>1.002</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.807</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.500</ci_lower_limit>
            <ci_upper_limit>1.304</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>1.924</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.193</ci_lower_limit>
            <ci_upper_limit>3.102</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.970</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.611</ci_lower_limit>
            <ci_upper_limit>1.541</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.905</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.561</ci_lower_limit>
            <ci_upper_limit>1.460</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>1.273</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.798</ci_lower_limit>
            <ci_upper_limit>2.030</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>2.383</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.474</ci_lower_limit>
            <ci_upper_limit>3.851</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>1.202</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.754</ci_lower_limit>
            <ci_upper_limit>1.915</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>1.120</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.689</ci_lower_limit>
            <ci_upper_limit>1.821</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>1.576</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.987</ci_lower_limit>
            <ci_upper_limit>2.516</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.504</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.316</ci_lower_limit>
            <ci_upper_limit>0.805</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.470</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.293</ci_lower_limit>
            <ci_upper_limit>0.754</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.662</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.414</ci_lower_limit>
            <ci_upper_limit>1.056</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>0.932</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.583</ci_lower_limit>
            <ci_upper_limit>1.492</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>1.312</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.831</ci_lower_limit>
            <ci_upper_limit>2.071</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric mean ratio at day 387</param_type>
            <param_value>1.407</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.880</ci_lower_limit>
            <ci_upper_limit>2.249</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>5.428</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4</ci_lower_limit>
            <ci_upper_limit>7.365</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>1.091</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.804</ci_lower_limit>
            <ci_upper_limit>1.481</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.759</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.559</ci_lower_limit>
            <ci_upper_limit>1.031</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>3.499</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.577</ci_lower_limit>
            <ci_upper_limit>4.751</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.982</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.722</ci_lower_limit>
            <ci_upper_limit>1.334</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.699</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.513</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>2.513</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.846</ci_lower_limit>
            <ci_upper_limit>3.421</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.201</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.149</ci_lower_limit>
            <ci_upper_limit>0.272</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.103</ci_lower_limit>
            <ci_upper_limit>0.189</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.645</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.476</ci_lower_limit>
            <ci_upper_limit>0.873</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.181</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.134</ci_lower_limit>
            <ci_upper_limit>0.245</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.129</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.095</ci_lower_limit>
            <ci_upper_limit>0.174</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.463</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.341</ci_lower_limit>
            <ci_upper_limit>0.628</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.696</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.514</ci_lower_limit>
            <ci_upper_limit>0.943</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>3.207</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.368</ci_lower_limit>
            <ci_upper_limit>4.343</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.665</ci_lower_limit>
            <ci_upper_limit>1.218</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.472</ci_lower_limit>
            <ci_upper_limit>0.868</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>2.303</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.7</ci_lower_limit>
            <ci_upper_limit>3.121</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>4.608</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.398</ci_lower_limit>
            <ci_upper_limit>6.249</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>1.293</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.954</ci_lower_limit>
            <ci_upper_limit>1.753</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.677</ci_lower_limit>
            <ci_upper_limit>1.249</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>3.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.436</ci_lower_limit>
            <ci_upper_limit>4.496</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.281</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.207</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.147</ci_lower_limit>
            <ci_upper_limit>0.271</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.718</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.529</ci_lower_limit>
            <ci_upper_limit>0.975</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>0.712</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.524</ci_lower_limit>
            <ci_upper_limit>0.966</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>2.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.886</ci_lower_limit>
            <ci_upper_limit>3.474</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>A difference was assumed to be statistically significant if the 2-sided 95% CI around the ratio of GMTs did not contain 1, in which case one group is either statistically significantly superior or statistically inferior to the other</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For pairwise vaccine group compared, least squares GMT and associated 2-sided 95% CI, median, minimum, and maximum HI titer values were determined. The two-sided 95% CIs was calculated and assessed against a non-inferiority margin of 0.5. Subsequently the same non-inferiority hypothesis was tested using a non-inferiority margin of 0.67.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio at day 29</param_type>
            <param_value>3.597</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.646</ci_lower_limit>
            <ci_upper_limit>4.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Responses With and Without Seasonal Influenza Vaccination for Year 2009 to 2010.</title>
        <description>HI antibody assay (used to assess immune responses in subjects following vaccination) according to the Committee for Medicinal Products for Human Use (CHMP) guidance: in adults ages 18 to 60 years are:The percentage of subjects with seroconversion or significant increase in HI antibody is &gt; 40%.The percentage of subjects achieving an HI titer ≥ 40 is &gt; 70% and The GMR is &gt; 2.5. All 3 criteria (seroconversion/significant increase, HI antibody titer ≥ 40, and GMR) had to be fulfilled to establish immunogenicity.Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.Subgroups without recent seasonal flu vaccine:PPS Day1, Day 1–22 and Day1–43 analysis set. N= 141, 147, 150, 148, 146, 146, 150, and 146 for Groups A, B, C, D, E, F, G, and H respectively. PPS Day 1–29 analysis set. N= 132, 140, 143, 139, 138, 136, 139, and 138 for Groups A, B, C, D, E, F, G,and H respectively.</description>
        <time_frame>Day 22, Day 29, Day 43</time_frame>
        <population>The analysis was done on PPS population</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>50% of MF59 with 3.75 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O2">
            <title>7.5 Without MF59</title>
            <description>1 dose of 7.5 µg A/H1N1</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>50% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O4">
            <title>7.5_(100)MF59</title>
            <description>100% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O5">
            <title>15 Without MF59</title>
            <description>1 dose of 15 µg A/H1N1</description>
          </group>
          <group group_id="O6">
            <title>15_(50)MF59</title>
            <description>50% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O7">
            <title>15_(100)MF59</title>
            <description>100% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O8">
            <title>30 Without MF59</title>
            <description>1 dose of 30 µg A/H1N1</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Responses With and Without Seasonal Influenza Vaccination for Year 2009 to 2010.</title>
          <description>HI antibody assay (used to assess immune responses in subjects following vaccination) according to the Committee for Medicinal Products for Human Use (CHMP) guidance: in adults ages 18 to 60 years are:The percentage of subjects with seroconversion or significant increase in HI antibody is &gt; 40%.The percentage of subjects achieving an HI titer ≥ 40 is &gt; 70% and The GMR is &gt; 2.5. All 3 criteria (seroconversion/significant increase, HI antibody titer ≥ 40, and GMR) had to be fulfilled to establish immunogenicity.Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.Subgroups without recent seasonal flu vaccine:PPS Day1, Day 1–22 and Day1–43 analysis set. N= 141, 147, 150, 148, 146, 146, 150, and 146 for Groups A, B, C, D, E, F, G, and H respectively. PPS Day 1–29 analysis set. N= 132, 140, 143, 139, 138, 136, 139, and 138 for Groups A, B, C, D, E, F, G,and H respectively.</description>
          <population>The analysis was done on PPS population</population>
          <units>percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="155"/>
                <count group_id="O6" value="157"/>
                <count group_id="O7" value="156"/>
                <count group_id="O8" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion (Day 22/Day 1)with seasonal flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="39" upper_limit="94"/>
                    <measurement group_id="O2" value="22" lower_limit="3" upper_limit="60"/>
                    <measurement group_id="O3" value="83" lower_limit="36" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O5" value="44" lower_limit="14" upper_limit="79"/>
                    <measurement group_id="O6" value="73" lower_limit="39" upper_limit="94"/>
                    <measurement group_id="O7" value="100" lower_limit="54" upper_limit="100"/>
                    <measurement group_id="O8" value="71" lower_limit="29" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 29/Day 1)with seasonal flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="72" upper_limit="100"/>
                    <measurement group_id="O2" value="67" lower_limit="30" upper_limit="93"/>
                    <measurement group_id="O3" value="83" lower_limit="36" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O5" value="67" lower_limit="30" upper_limit="93"/>
                    <measurement group_id="O6" value="100" lower_limit="72" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="48" upper_limit="100"/>
                    <measurement group_id="O8" value="83" lower_limit="36" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 43/Day 1)with seasonal flu va</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O2" value="78" lower_limit="40" upper_limit="97"/>
                    <measurement group_id="O3" value="67" lower_limit="22" upper_limit="96"/>
                    <measurement group_id="O4" value="88" lower_limit="47" upper_limit="100"/>
                    <measurement group_id="O5" value="78" lower_limit="40" upper_limit="97"/>
                    <measurement group_id="O6" value="100" lower_limit="72" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="54" upper_limit="100"/>
                    <measurement group_id="O8" value="86" lower_limit="42" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 1)_ with seasonal flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="2" upper_limit="52"/>
                    <measurement group_id="O2" value="22" lower_limit="3" upper_limit="60"/>
                    <measurement group_id="O3" value="50" lower_limit="12" upper_limit="88"/>
                    <measurement group_id="O4" value="38" lower_limit="9" upper_limit="76"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="34"/>
                    <measurement group_id="O6" value="9" lower_limit="0" upper_limit="41"/>
                    <measurement group_id="O7" value="17" lower_limit="0" upper_limit="64"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 22)_ with seasonal flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="39" upper_limit="94"/>
                    <measurement group_id="O2" value="33" lower_limit="7" upper_limit="70"/>
                    <measurement group_id="O3" value="100" lower_limit="54" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O5" value="44" lower_limit="14" upper_limit="79"/>
                    <measurement group_id="O6" value="73" lower_limit="39" upper_limit="94"/>
                    <measurement group_id="O7" value="100" lower_limit="54" upper_limit="100"/>
                    <measurement group_id="O8" value="71" lower_limit="29" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 29)_ with seasonal flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="72" upper_limit="100"/>
                    <measurement group_id="O2" value="67" lower_limit="30" upper_limit="93"/>
                    <measurement group_id="O3" value="100" lower_limit="54" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O5" value="67" lower_limit="30" upper_limit="93"/>
                    <measurement group_id="O6" value="100" lower_limit="72" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="48" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="54" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 43)_ with seasonal flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="72" upper_limit="100"/>
                    <measurement group_id="O2" value="78" lower_limit="40" upper_limit="97"/>
                    <measurement group_id="O3" value="100" lower_limit="54" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O5" value="78" lower_limit="40" upper_limit="97"/>
                    <measurement group_id="O6" value="100" lower_limit="72" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="54" upper_limit="100"/>
                    <measurement group_id="O8" value="86" lower_limit="42" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 22/Day 1)without flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="75" upper_limit="88"/>
                    <measurement group_id="O2" value="47" lower_limit="39" upper_limit="55"/>
                    <measurement group_id="O3" value="77" lower_limit="70" upper_limit="84"/>
                    <measurement group_id="O4" value="88" lower_limit="81" upper_limit="93"/>
                    <measurement group_id="O5" value="59" lower_limit="50" upper_limit="67"/>
                    <measurement group_id="O6" value="82" lower_limit="75" upper_limit="88"/>
                    <measurement group_id="O7" value="91" lower_limit="86" upper_limit="95"/>
                    <measurement group_id="O8" value="60" lower_limit="51" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 29/Day 1)without flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="79" lower_limit="71" upper_limit="85"/>
                    <measurement group_id="O3" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O4" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O5" value="88" lower_limit="82" upper_limit="93"/>
                    <measurement group_id="O6" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O8" value="94" lower_limit="89" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 43/Day 1)without flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="78" lower_limit="70" upper_limit="84"/>
                    <measurement group_id="O3" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O4" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O5" value="85" lower_limit="78" upper_limit="90"/>
                    <measurement group_id="O6" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O7" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O8" value="88" lower_limit="82" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 1) without flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="6" upper_limit="16"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="14"/>
                    <measurement group_id="O3" value="11" lower_limit="7" upper_limit="18"/>
                    <measurement group_id="O4" value="9" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="O5" value="16" lower_limit="11" upper_limit="23"/>
                    <measurement group_id="O6" value="9" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="O7" value="7" lower_limit="4" upper_limit="13"/>
                    <measurement group_id="O8" value="13" lower_limit="8" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 22)without flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="77" upper_limit="90"/>
                    <measurement group_id="O2" value="49" lower_limit="41" upper_limit="57"/>
                    <measurement group_id="O3" value="80" lower_limit="73" upper_limit="86"/>
                    <measurement group_id="O4" value="91" lower_limit="85" upper_limit="95"/>
                    <measurement group_id="O5" value="62" lower_limit="53" upper_limit="70"/>
                    <measurement group_id="O6" value="83" lower_limit="76" upper_limit="89"/>
                    <measurement group_id="O7" value="93" lower_limit="88" upper_limit="97"/>
                    <measurement group_id="O8" value="65" lower_limit="57" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 29) without flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="79" lower_limit="72" upper_limit="86"/>
                    <measurement group_id="O3" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O5" value="90" lower_limit="84" upper_limit="94"/>
                    <measurement group_id="O6" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O8" value="96" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 43) without flu vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="79" lower_limit="71" upper_limit="85"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O4" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O5" value="88" lower_limit="81" upper_limit="93"/>
                    <measurement group_id="O6" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O8" value="92" lower_limit="86" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</title>
        <description>Immunogenicity was measured in terms of GMTs of Subgroups with receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines
Subgroups without recent seasonal flu vaccine:
PPS Day 1, Day 1–22 and Day 1–43 analysis set. N= 141, 147, 150, 148, 146, 146, 150, and 146 for Groups A, B, C, D, E, F, G, and H respectively.
PPS Day 1–29 analysis set. N= 132, 140, 143, 139, 138, 136, 139, and 138 for Groups A, B, C, D, E, F,G, and H respectively.
Subgroups with recent seasonal flu vaccine:PPS Day 1–22 and Day 1-43 analysis set. N= 11, 9, 6, 8, 9, 11, 6, and 7 for Groups A, B, C, D, E, F, G,and H respectively.
PPS Day 1–29 analysis set. N= 11, 9, 6, 7, 9, 11, 5, and 6 for Groups A, B, C, D, E, F, G, and H respectively</description>
        <time_frame>Day 1, Day 22, Day 29, Day 43</time_frame>
        <population>The analysis was done on PPS population.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>50% of MF59 with 3.75 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O2">
            <title>7.5 Without MF59</title>
            <description>1 dose of 7.5 µg A/H1N1</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>50% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O4">
            <title>7.5_(100)MF59</title>
            <description>100% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O5">
            <title>15 Without MF59</title>
            <description>1 dose of 15 µg A/H1N1</description>
          </group>
          <group group_id="O6">
            <title>15_(50)MF59</title>
            <description>50% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O7">
            <title>15_(100)MF59</title>
            <description>100% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O8">
            <title>30 Without MF59</title>
            <description>1 dose of 30 µg A/H1N1</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</title>
          <description>Immunogenicity was measured in terms of GMTs of Subgroups with receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines
Subgroups without recent seasonal flu vaccine:
PPS Day 1, Day 1–22 and Day 1–43 analysis set. N= 141, 147, 150, 148, 146, 146, 150, and 146 for Groups A, B, C, D, E, F, G, and H respectively.
PPS Day 1–29 analysis set. N= 132, 140, 143, 139, 138, 136, 139, and 138 for Groups A, B, C, D, E, F,G, and H respectively.
Subgroups with recent seasonal flu vaccine:PPS Day 1–22 and Day 1-43 analysis set. N= 11, 9, 6, 8, 9, 11, 6, and 7 for Groups A, B, C, D, E, F, G,and H respectively.
PPS Day 1–29 analysis set. N= 11, 9, 6, 7, 9, 11, 5, and 6 for Groups A, B, C, D, E, F, G, and H respectively</description>
          <population>The analysis was done on PPS population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="155"/>
                <count group_id="O6" value="157"/>
                <count group_id="O7" value="156"/>
                <count group_id="O8" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1_with seasonal flu vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" lower_limit="2.16" upper_limit="18"/>
                    <measurement group_id="O2" value="12" lower_limit="3.63" upper_limit="42"/>
                    <measurement group_id="O3" value="22" lower_limit="5.54" upper_limit="90"/>
                    <measurement group_id="O4" value="15" lower_limit="4.5" upper_limit="47"/>
                    <measurement group_id="O5" value="5.42" lower_limit="1.75" upper_limit="17"/>
                    <measurement group_id="O6" value="5.99" lower_limit="2.16" upper_limit="17"/>
                    <measurement group_id="O7" value="15" lower_limit="3.94" upper_limit="565"/>
                    <measurement group_id="O8" value="9.36" lower_limit="2.69" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22_ with seasonal flu vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="9.11" upper_limit="146"/>
                    <measurement group_id="O2" value="44" lower_limit="8.93" upper_limit="217"/>
                    <measurement group_id="O3" value="196" lower_limit="32" upper_limit="1213"/>
                    <measurement group_id="O4" value="209" lower_limit="45" upper_limit="976"/>
                    <measurement group_id="O5" value="48" lower_limit="11" upper_limit="210"/>
                    <measurement group_id="O6" value="44" lower_limit="11" upper_limit="166"/>
                    <measurement group_id="O7" value="345" lower_limit="61" upper_limit="1961"/>
                    <measurement group_id="O8" value="111" lower_limit="22" upper_limit="567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29_ with seasonal flu vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278" lower_limit="90" upper_limit="856"/>
                    <measurement group_id="O2" value="171" lower_limit="47" upper_limit="625"/>
                    <measurement group_id="O3" value="785" lower_limit="178" upper_limit="3450"/>
                    <measurement group_id="O4" value="1186" lower_limit="317" upper_limit="4440"/>
                    <measurement group_id="O5" value="137" lower_limit="41" upper_limit="457"/>
                    <measurement group_id="O6" value="670" lower_limit="226" upper_limit="1988"/>
                    <measurement group_id="O7" value="771" lower_limit="164" upper_limit="3628"/>
                    <measurement group_id="O8" value="184" lower_limit="43" upper_limit="791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43_ with seasonal flu vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260" lower_limit="102" upper_limit="665"/>
                    <measurement group_id="O2" value="182" lower_limit="62" upper_limit="537"/>
                    <measurement group_id="O3" value="503" lower_limit="146" upper_limit="1729"/>
                    <measurement group_id="O4" value="594" lower_limit="209" upper_limit="1687"/>
                    <measurement group_id="O5" value="81" lower_limit="30" upper_limit="221"/>
                    <measurement group_id="O6" value="663" lower_limit="268" upper_limit="1639"/>
                    <measurement group_id="O7" value="1035" lower_limit="319" upper_limit="3363"/>
                    <measurement group_id="O8" value="228" lower_limit="75" upper_limit="689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1_without seasonal flu vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.54" lower_limit="7.03" upper_limit="10"/>
                    <measurement group_id="O2" value="7.08" lower_limit="5.84" upper_limit="8.59"/>
                    <measurement group_id="O3" value="8.3" lower_limit="6.86" upper_limit="10"/>
                    <measurement group_id="O4" value="7.76" lower_limit="6.41" upper_limit="9.41"/>
                    <measurement group_id="O5" value="9.35" lower_limit="7.71" upper_limit="11"/>
                    <measurement group_id="O6" value="7.47" lower_limit="6.15" upper_limit="9.08"/>
                    <measurement group_id="O7" value="6.8" lower_limit="5.61" upper_limit="8.24"/>
                    <measurement group_id="O8" value="9.1" lower_limit="7.51" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22_ without seasonal flu vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" lower_limit="83" upper_limit="161"/>
                    <measurement group_id="O2" value="28" lower_limit="20" upper_limit="38"/>
                    <measurement group_id="O3" value="85" lower_limit="61" upper_limit="117"/>
                    <measurement group_id="O4" value="159" lower_limit="115" upper_limit="220"/>
                    <measurement group_id="O5" value="52" lower_limit="38" upper_limit="72"/>
                    <measurement group_id="O6" value="109" lower_limit="79" upper_limit="152"/>
                    <measurement group_id="O7" value="158" lower_limit="114" upper_limit="218"/>
                    <measurement group_id="O8" value="62" lower_limit="45" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29_ without seasonal flu vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="810" lower_limit="633" upper_limit="1037"/>
                    <measurement group_id="O2" value="144" lower_limit="113" upper_limit="183"/>
                    <measurement group_id="O3" value="669" lower_limit="527" upper_limit="849"/>
                    <measurement group_id="O4" value="968" lower_limit="760" upper_limit="1232"/>
                    <measurement group_id="O5" value="228" lower_limit="179" upper_limit="291"/>
                    <measurement group_id="O6" value="756" lower_limit="591" upper_limit="966"/>
                    <measurement group_id="O7" value="1080" lower_limit="847" upper_limit="1377"/>
                    <measurement group_id="O8" value="297" lower_limit="233" upper_limit="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43_ without seasonal flu vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600" lower_limit="477" upper_limit="753"/>
                    <measurement group_id="O2" value="115" lower_limit="92" upper_limit="144"/>
                    <measurement group_id="O3" value="477" lower_limit="381" upper_limit="596"/>
                    <measurement group_id="O4" value="643" lower_limit="514" upper_limit="805"/>
                    <measurement group_id="O5" value="182" lower_limit="145" upper_limit="228"/>
                    <measurement group_id="O6" value="520" lower_limit="414" upper_limit="653"/>
                    <measurement group_id="O7" value="770" lower_limit="615" upper_limit="963"/>
                    <measurement group_id="O8" value="224" lower_limit="179" upper_limit="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Response Based on Baseline Seropositivity</title>
        <description>Subgroup analysis based on Subjects with seropositivity (pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10) at baseline.
Subgroups with baseline HI titer &lt; 1:10: PPS Day 1–29 analysis set. N= 104, 116, 111, 107, 109, 113,120, and 103 for Groups A, B, C, D, E, F, G, and H respectively.
Subgroups with baseline HI titer ≥ 1:10: PPS Day 1–29 analysis set. N= 39, 33, 38, 39, 38, 34, 24, and 41 for Groups A, B, C, D, E, F, G, and H respectively.</description>
        <time_frame>Day 22, Day 29 and Day 43</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>50% of MF59 with 3.75 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O2">
            <title>7.5 Without MF59</title>
            <description>1 dose of 7.5 µg A/H1N1</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>50% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O4">
            <title>7.5_(100)MF59</title>
            <description>100% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O5">
            <title>15 Without MF59</title>
            <description>1 dose of 15 µg A/H1N1</description>
          </group>
          <group group_id="O6">
            <title>15_(50)MF59</title>
            <description>50% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O7">
            <title>15_(100)MF59</title>
            <description>100% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O8">
            <title>30 Without MF59</title>
            <description>1 dose of 30 µg A/H1N1</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response Based on Baseline Seropositivity</title>
          <description>Subgroup analysis based on Subjects with seropositivity (pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10) at baseline.
Subgroups with baseline HI titer &lt; 1:10: PPS Day 1–29 analysis set. N= 104, 116, 111, 107, 109, 113,120, and 103 for Groups A, B, C, D, E, F, G, and H respectively.
Subgroups with baseline HI titer ≥ 1:10: PPS Day 1–29 analysis set. N= 39, 33, 38, 39, 38, 34, 24, and 41 for Groups A, B, C, D, E, F, G, and H respectively.</description>
          <units>percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="155"/>
                <count group_id="O6" value="157"/>
                <count group_id="O7" value="156"/>
                <count group_id="O8" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion (Day 22/Day 1)_baseline HI &lt; 1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="72" upper_limit="88"/>
                    <measurement group_id="O2" value="39" lower_limit="30" upper_limit="48"/>
                    <measurement group_id="O3" value="79" lower_limit="71" upper_limit="86"/>
                    <measurement group_id="O4" value="90" lower_limit="84" upper_limit="95"/>
                    <measurement group_id="O5" value="54" lower_limit="44" upper_limit="63"/>
                    <measurement group_id="O6" value="78" lower_limit="69" upper_limit="85"/>
                    <measurement group_id="O7" value="92" lower_limit="86" upper_limit="96"/>
                    <measurement group_id="O8" value="61" lower_limit="52" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 29/Day 1)_baseline HI &lt; 1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="75" lower_limit="66" upper_limit="83"/>
                    <measurement group_id="O3" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="98" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O5" value="85" lower_limit="77" upper_limit="91"/>
                    <measurement group_id="O6" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O8" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 43/Day 1)_baseline HI &lt; 1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="75" lower_limit="67" upper_limit="83"/>
                    <measurement group_id="O3" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O5" value="83" lower_limit="75" upper_limit="90"/>
                    <measurement group_id="O6" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O8" value="91" lower_limit="84" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 1)_ baseline HI &lt;1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 22)_ baseline HI &lt;1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="72" upper_limit="88"/>
                    <measurement group_id="O2" value="39" lower_limit="30" upper_limit="48"/>
                    <measurement group_id="O3" value="79" lower_limit="71" upper_limit="86"/>
                    <measurement group_id="O4" value="90" lower_limit="84" upper_limit="95"/>
                    <measurement group_id="O5" value="54" lower_limit="44" upper_limit="63"/>
                    <measurement group_id="O6" value="78" lower_limit="69" upper_limit="85"/>
                    <measurement group_id="O7" value="92" lower_limit="86" upper_limit="96"/>
                    <measurement group_id="O8" value="61" lower_limit="52" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 29)_ baseline HI &lt;1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="75" lower_limit="66" upper_limit="83"/>
                    <measurement group_id="O3" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="98" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O5" value="85" lower_limit="77" upper_limit="91"/>
                    <measurement group_id="O6" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O8" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 43)_ baseline HI &lt;1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="75" lower_limit="67" upper_limit="83"/>
                    <measurement group_id="O3" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O5" value="83" lower_limit="75" upper_limit="90"/>
                    <measurement group_id="O6" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O8" value="91" lower_limit="84" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 22/Day 1)_baseline HI ≥ 1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="69" upper_limit="93"/>
                    <measurement group_id="O2" value="69" lower_limit="51" upper_limit="83"/>
                    <measurement group_id="O3" value="73" lower_limit="57" upper_limit="86"/>
                    <measurement group_id="O4" value="83" lower_limit="68" upper_limit="93"/>
                    <measurement group_id="O5" value="71" lower_limit="54" upper_limit="84"/>
                    <measurement group_id="O6" value="95" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O7" value="89" lower_limit="72" upper_limit="98"/>
                    <measurement group_id="O8" value="57" lower_limit="41" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 29/Day 1)_baseline HI ≥ 1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="88" lower_limit="72" upper_limit="97"/>
                    <measurement group_id="O3" value="95" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O4" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O5" value="92" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O6" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O8" value="85" lower_limit="71" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (Day 43/Day 1)_baseline HI ≥ 1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="84" upper_limit="99"/>
                    <measurement group_id="O2" value="86" lower_limit="70" upper_limit="95"/>
                    <measurement group_id="O3" value="88" lower_limit="74" upper_limit="96"/>
                    <measurement group_id="O4" value="95" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O5" value="88" lower_limit="74" upper_limit="96"/>
                    <measurement group_id="O6" value="97" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O7" value="96" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O8" value="81" lower_limit="66" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 1)_ baseline HI ≥1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="24" upper_limit="54"/>
                    <measurement group_id="O2" value="40" lower_limit="24" upper_limit="58"/>
                    <measurement group_id="O3" value="49" lower_limit="33" upper_limit="65"/>
                    <measurement group_id="O4" value="41" lower_limit="26" upper_limit="58"/>
                    <measurement group_id="O5" value="59" lower_limit="42" upper_limit="74"/>
                    <measurement group_id="O6" value="38" lower_limit="22" upper_limit="55"/>
                    <measurement group_id="O7" value="43" lower_limit="24" upper_limit="63"/>
                    <measurement group_id="O8" value="45" lower_limit="30" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 22)_ baseline HI ≥1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="77" upper_limit="97"/>
                    <measurement group_id="O2" value="80" lower_limit="63" upper_limit="92"/>
                    <measurement group_id="O3" value="85" lower_limit="71" upper_limit="94"/>
                    <measurement group_id="O4" value="93" lower_limit="80" upper_limit="98"/>
                    <measurement group_id="O5" value="80" lower_limit="65" upper_limit="91"/>
                    <measurement group_id="O6" value="97" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="O8" value="76" lower_limit="61" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 29)_ baseline HI ≥1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O2" value="91" lower_limit="76" upper_limit="98"/>
                    <measurement group_id="O3" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O5" value="97" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O8" value="95" lower_limit="83" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI titer ≥1:40 (Day 43)_ baseline HI ≥1:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O2" value="91" lower_limit="77" upper_limit="98"/>
                    <measurement group_id="O3" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O5" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O7" value="100" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="O8" value="93" lower_limit="81" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) Based on Baseline Seropositivity</title>
        <description>Subgroup analysis based on Subjects with seropositivity (pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10) at baseline.
Immunogenicity responses in subjects who are seropositive (A/H1N1 2009 HI titer ≥ 1:10) at Baseline [Day 1 (pre-vaccination)] as compared to those who are seronegative (HI titer &lt; 1:10).</description>
        <time_frame>Day 1, Day 22, Day 29, Day 43</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>50% of MF59 with 3.75 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O2">
            <title>7.5 Without MF59</title>
            <description>1 dose of 7.5 µg A/H1N1</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>50% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O4">
            <title>7.5_(100)MF59</title>
            <description>100% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O5">
            <title>15 Without MF59</title>
            <description>1 dose of 15 µg A/H1N1</description>
          </group>
          <group group_id="O6">
            <title>15_(50)MF59</title>
            <description>50% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O7">
            <title>15_(100)MF59</title>
            <description>100% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O8">
            <title>30 Without MF59</title>
            <description>1 dose of 30 µg A/H1N1</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) Based on Baseline Seropositivity</title>
          <description>Subgroup analysis based on Subjects with seropositivity (pre-vaccination HI antibody titer &lt; 1:10 and prevaccination HI antibody titer ≥ 1:10) at baseline.
Immunogenicity responses in subjects who are seropositive (A/H1N1 2009 HI titer ≥ 1:10) at Baseline [Day 1 (pre-vaccination)] as compared to those who are seronegative (HI titer &lt; 1:10).</description>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="156"/>
                <count group_id="O5" value="155"/>
                <count group_id="O6" value="157"/>
                <count group_id="O7" value="156"/>
                <count group_id="O8" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMTDay 1 HI &lt;1:10(110,121,115,115,114,120,128,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5.1"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5.1"/>
                    <measurement group_id="O3" value="5.1" lower_limit="5" upper_limit="5.1"/>
                    <measurement group_id="O4" value="5.1" lower_limit="5" upper_limit="5.1"/>
                    <measurement group_id="O5" value="5" lower_limit="5" upper_limit="5.1"/>
                    <measurement group_id="O6" value="5" lower_limit="5" upper_limit="5.07"/>
                    <measurement group_id="O7" value="5.1" lower_limit="5" upper_limit="5.2"/>
                    <measurement group_id="O8" value="5.1" lower_limit="5" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMTDay 22 HI&lt;1:10(110,121,115,115,114,120,128,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="57" upper_limit="111"/>
                    <measurement group_id="O2" value="18" lower_limit="13" upper_limit="25"/>
                    <measurement group_id="O3" value="62" lower_limit="45" upper_limit="85"/>
                    <measurement group_id="O4" value="130" lower_limit="94" upper_limit="180"/>
                    <measurement group_id="O5" value="26" lower_limit="19" upper_limit="36"/>
                    <measurement group_id="O6" value="72" lower_limit="52" upper_limit="98"/>
                    <measurement group_id="O7" value="130" lower_limit="96" upper_limit="177"/>
                    <measurement group_id="O8" value="39" lower_limit="28" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMTDay 29HI &lt;1:10(110,121,115,115,114,120,128,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="664" lower_limit="505" upper_limit="872"/>
                    <measurement group_id="O2" value="100" lower_limit="78" upper_limit="130"/>
                    <measurement group_id="O3" value="638" lower_limit="490" upper_limit="830"/>
                    <measurement group_id="O4" value="885" lower_limit="676" upper_limit="1157"/>
                    <measurement group_id="O5" value="149" lower_limit="114" upper_limit="194"/>
                    <measurement group_id="O6" value="685" lower_limit="527" upper_limit="890"/>
                    <measurement group_id="O7" value="950" lower_limit="736" upper_limit="1227"/>
                    <measurement group_id="O8" value="234" lower_limit="179" upper_limit="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMTDay 43HI &lt;1:10(110,121,115,115,114,120,128,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490" lower_limit="381" upper_limit="630"/>
                    <measurement group_id="O2" value="85" lower_limit="67" upper_limit="108"/>
                    <measurement group_id="O3" value="437" lower_limit="342" upper_limit="559"/>
                    <measurement group_id="O4" value="568" lower_limit="444" upper_limit="727"/>
                    <measurement group_id="O5" value="121" lower_limit="95" upper_limit="155"/>
                    <measurement group_id="O6" value="463" lower_limit="363" upper_limit="590"/>
                    <measurement group_id="O7" value="717" lower_limit="566" upper_limit="908"/>
                    <measurement group_id="O8" value="177" lower_limit="138" upper_limit="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT Day 1 HI ≥ 1:10(42,35,41,41,41,37,28,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="28" upper_limit="57"/>
                    <measurement group_id="O2" value="32" lower_limit="21" upper_limit="47"/>
                    <measurement group_id="O3" value="47" lower_limit="32" upper_limit="68"/>
                    <measurement group_id="O4" value="32" lower_limit="22" upper_limit="46"/>
                    <measurement group_id="O5" value="52" lower_limit="36" upper_limit="75"/>
                    <measurement group_id="O6" value="35" lower_limit="24" upper_limit="52"/>
                    <measurement group_id="O7" value="40" lower_limit="26" upper_limit="63"/>
                    <measurement group_id="O8" value="48" lower_limit="33" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT Day 22_HI ≥1:10(42,35,41,41,41,37,28,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343" lower_limit="187" upper_limit="628"/>
                    <measurement group_id="O2" value="132" lower_limit="68" upper_limit="258"/>
                    <measurement group_id="O3" value="311" lower_limit="164" upper_limit="590"/>
                    <measurement group_id="O4" value="320" lower_limit="171" upper_limit="599"/>
                    <measurement group_id="O5" value="284" lower_limit="151" upper_limit="532"/>
                    <measurement group_id="O6" value="417" lower_limit="217" upper_limit="802"/>
                    <measurement group_id="O7" value="460" lower_limit="219" upper_limit="965"/>
                    <measurement group_id="O8" value="252" lower_limit="134" upper_limit="475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT Day 29_HI ≥1:10(42,35,41,41,41,37,28,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1178" lower_limit="782" upper_limit="1776"/>
                    <measurement group_id="O2" value="460" lower_limit="294" upper_limit="721"/>
                    <measurement group_id="O3" value="1063" lower_limit="689" upper_limit="1640"/>
                    <measurement group_id="O4" value="1281" lower_limit="843" upper_limit="1948"/>
                    <measurement group_id="O5" value="543" lower_limit="356" upper_limit="830"/>
                    <measurement group_id="O6" value="1197" lower_limit="771" upper_limit="1857"/>
                    <measurement group_id="O7" value="2088" lower_limit="1240" upper_limit="3516"/>
                    <measurement group_id="O8" value="641" lower_limit="422" upper_limit="973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT Day 43_HI ≥1:10(42,35,41,41,41,37,28,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="876" lower_limit="604" upper_limit="1271"/>
                    <measurement group_id="O2" value="320" lower_limit="212" upper_limit="482"/>
                    <measurement group_id="O3" value="657" lower_limit="443" upper_limit="974"/>
                    <measurement group_id="O4" value="881" lower_limit="599" upper_limit="1295"/>
                    <measurement group_id="O5" value="464" lower_limit="316" upper_limit="684"/>
                    <measurement group_id="O6" value="838" lower_limit="561" upper_limit="1253"/>
                    <measurement group_id="O7" value="1184" lower_limit="751" upper_limit="1867"/>
                    <measurement group_id="O8" value="428" lower_limit="290" upper_limit="631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Symptoms After the First Vaccination</title>
        <description>Solicited local and systemic reactions were assessed after the first vaccination by vaccine group. Source Vocabulary Name: MedDRA (13.1).</description>
        <time_frame>7 days after first vaccination</time_frame>
        <population>The analysis was performed on safety set population</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>50% of MF59 with 3.75 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O2">
            <title>7.5 Without MF59</title>
            <description>1 dose of 7.5 µg A/H1N1</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>50% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O4">
            <title>7.5_(100)MF59</title>
            <description>100% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O5">
            <title>15 Without MF59</title>
            <description>1 dose of 15 µg A/H1N1</description>
          </group>
          <group group_id="O6">
            <title>15_(50)MF59</title>
            <description>50% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O7">
            <title>15_(100)MF59</title>
            <description>100% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O8">
            <title>30 Without MF59</title>
            <description>1 dose of 30 µg A/H1N1</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Symptoms After the First Vaccination</title>
          <description>Solicited local and systemic reactions were assessed after the first vaccination by vaccine group. Source Vocabulary Name: MedDRA (13.1).</description>
          <population>The analysis was performed on safety set population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="167"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="166"/>
                <count group_id="O8" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="86"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="65"/>
                    <measurement group_id="O7" value="72"/>
                    <measurement group_id="O8" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="78"/>
                    <measurement group_id="O7" value="69"/>
                    <measurement group_id="O8" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed home</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic./anti pyretic used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Symptoms After the Second Vaccination</title>
        <description>Solicited local and systemic reactions were assessed after the second vaccination by vaccine group.Source Vocabulary Name: MedDRA (13.1)</description>
        <time_frame>7 days after second vaccination</time_frame>
        <population>The analysis was performed on safety set population</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>50% of MF59 with 3.75 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O2">
            <title>7.5 Without MF59</title>
            <description>1 dose of 7.5 µg A/H1N1</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>50% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O4">
            <title>7.5_(100)MF59</title>
            <description>100% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O5">
            <title>15 Without MF59</title>
            <description>1 dose of 15 µg A/H1N1</description>
          </group>
          <group group_id="O6">
            <title>15_(50)MF59</title>
            <description>50% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O7">
            <title>15_(100)MF59</title>
            <description>100% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O8">
            <title>30 Without MF59</title>
            <description>1 dose of 30 µg A/H1N1</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Symptoms After the Second Vaccination</title>
          <description>Solicited local and systemic reactions were assessed after the second vaccination by vaccine group.Source Vocabulary Name: MedDRA (13.1)</description>
          <population>The analysis was performed on safety set population</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
                <count group_id="O5" value="162"/>
                <count group_id="O6" value="167"/>
                <count group_id="O7" value="162"/>
                <count group_id="O8" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="59"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="57"/>
                    <measurement group_id="O7" value="48"/>
                    <measurement group_id="O8" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="65"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="67"/>
                    <measurement group_id="O7" value="57"/>
                    <measurement group_id="O8" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed home</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/anti pyretic used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Safety was measured in terms of the Number of Participants Reporting Unsolicited AEs. Source Vocabulary Name: MedDRA (13.1)</description>
        <time_frame>Safety monitoring periods were the Primary Period: Day 1 (1st vaccination) through ≤21 days post second vaccination, and the Follow-up Period: &gt;21 Days post second vaccination to 12 months after second vaccination</time_frame>
        <population>The analysis was done on unsolicited safety set population.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>50% of MF59 with 3.75 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O2">
            <title>7.5 Without MF59</title>
            <description>1 dose of 7.5 µg A/H1N1</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>50% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O4">
            <title>7.5_(100)MF59</title>
            <description>100% of MF59 with 7.5 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O5">
            <title>15 Without MF59</title>
            <description>1 dose of 15 µg A/H1N1</description>
          </group>
          <group group_id="O6">
            <title>15_(50)MF59</title>
            <description>50% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O7">
            <title>15_(100)MF59</title>
            <description>100% of MF59 with 15 µg A/H1N1 antigen</description>
          </group>
          <group group_id="O8">
            <title>30 Without MF59</title>
            <description>1 dose of 30 µg A/H1N1</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Unsolicited Adverse Events (AEs)</title>
          <description>Safety was measured in terms of the Number of Participants Reporting Unsolicited AEs. Source Vocabulary Name: MedDRA (13.1)</description>
          <population>The analysis was done on unsolicited safety set population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="169"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="168"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="167"/>
                <count group_id="O8" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs: all (Days 1–43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="86"/>
                    <measurement group_id="O6" value="93"/>
                    <measurement group_id="O7" value="79"/>
                    <measurement group_id="O8" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs: all (Days 1–43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to premature withdrawal (Days 1–43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to new onset of chronic disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to medically attended visits(Days 1–43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs: all (Days 44–387)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="90"/>
                    <measurement group_id="O6" value="101"/>
                    <measurement group_id="O7" value="90"/>
                    <measurement group_id="O8" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs: all (Days 44–387)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to premature withdrawal (Days 44–387)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to new onset of chronic dis.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to medically attended visit(Days44–387)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="90"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="89"/>
                    <measurement group_id="O8" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events (AEs) and serious adverse events (SAEs) were collected for the whole study (study day 1 to day 387).</time_frame>
      <desc>If the adverse event was solicited then the assessment was entered as systematic. However, if the adverse event was not solicited (unsolicited), then the assessment was entered as non-systematic.</desc>
      <group_list>
        <group group_id="E1">
          <title>3.75_(50)MF59</title>
          <description>50% of MF59 with 3.75 µg A/H1N1 antigen</description>
        </group>
        <group group_id="E2">
          <title>7.5 Without MF59</title>
          <description>1 dose of 7.5 µg A/H1N1</description>
        </group>
        <group group_id="E3">
          <title>7.5_(50)MF59</title>
          <description>50% of MF59 with 7.5 µg A/H1N1 antigen</description>
        </group>
        <group group_id="E4">
          <title>7.5_(100)MF59</title>
          <description>100% of MF59 with 7.5 µg A/H1N1 antigen</description>
        </group>
        <group group_id="E5">
          <title>15 Without MF59</title>
          <description>1 dose of 15 µg A/H1N1</description>
        </group>
        <group group_id="E6">
          <title>15_(50)MF59</title>
          <description>50% of MF59 with 15 µg A/H1N1 antigen</description>
        </group>
        <group group_id="E7">
          <title>15_(100)MF59</title>
          <description>100% of MF59 with 15 µg A/H1N1 antigen</description>
        </group>
        <group group_id="E8">
          <title>30 Without MF59</title>
          <description>1 dose of 30 µg A/H1N1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen Impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Chronic Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Otitis Media Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Staphylococcal Scalded Skin Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Foreign Body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Ulna Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Bipolar Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Intermittent Explosive Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Oppositional Defiant Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Post-Traumatic Stress Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pharyngeal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling Face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="169" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="168" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="168" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="168" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="167" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="169" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="34" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="117" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="85" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="99" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="100" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="89" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Upper respiratory track infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="28" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="40" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="38" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="168"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="167"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegContactVacUS.nvdit@Novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

